СатерексCompany News

SatRx LLC Announces First Registration in Russia of SatRx® (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes

Posted: 09 June 2016

June 9, 2016 – Today, at the largest global biotech forum, BIO International Convention, that took place in San Francisco, USA, SatRx LLC, a ChemRar company specializing in research and development in the fields of diabetes and cardiometabolic disorders, announced the first market registration of its innovative drug for the treatment of Type 2 diabetes, SatRx® (gosogliptin), in Russia.

According to the World Health Organization, diabetes is one of the four most socially significant diseases, responsible for 80% of deaths from non-communicable diseases worldwide. Diabetes affects one in ten people in the world, with Type 2 diabetes (or non-insulin-dependent diabetes) accounting for about 90% of all cases.

SatRx® is a new drug for treatment of Type 2 diabetes that belongs to the class of inhibitors of dipeptidyl peptidase-4 (DPP-4, DPP-IV), the enzyme responsible for the fast inactivation of the incretin hormones that stimulate insulin secretion in response to food intake. By inhibiting the activity of DPP-4, SatRx prolongs the blood-life of incretin hormones, improving blood glucose control, enhancing the insulin secretory response, and increasing insulin sensitivity.

Fig. - Mechanism of SatRx® action

In 2012, SatRx LLC, a ChemRar company, obtained an exclusive global (excluding China) license for the development, registration and commercialization of the Phase 2 drug candidate as well as its combinations from Pfizer Inc. SatRx secured an equity investment from ChemRar and a development contract with the Ministry of Industry and Trade of the Russian Federation under the framework of the “PharmaMed-2020” program, initiated by the Russian government to promote domestic drug development and modernization of the pharmaceutical industry. Under the "PharmaMed-2020" program, the Russian government plans for 90% of essential drugs to be produced locally by 2020.

"The first market registration of the SatRx drug is an important milestone for ChemRar in its commitment to developing breakthrough treatments, diagnostics, and mechanisms for monitoring and controlling diabetes,” stated Nikolay Savchuk, member of the Board of Directors of ChemRar High-Tech Center. "We are pleased to see that our cooperation with Pfizer will allow Russian patients with Type 2 diabetes to have access to new innovative medicines that have been developed internationally and will be manufactured domestically."

About SatRx LLC 
SatRx LLC, a pharmaceutical company established in 2010 as part of the ChemRar High-Tech Center, is focused on the development and registration of innovative drugs for the treatment of Type 2 diabetes and metabolic syndrome. 

About ChemRar 
ChemRar High-Tech Center (HTC) is a group of research, manufacturing, and investment companies engaged in the development, manufacturing and commercialization of innovative drugs for the treatment of patients with life threatening diseases in Russia and worldwide.   

Contacts for media: 

Surina Elena 
ChemRar RnD Institute 
Phone: 8 (495) 925 30 74